MIM
BNTC icon

MetLife Investment Management’s Benitec Biopharma BNTC Stock Holding History

MetLife Investment Management’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$100K Hold
9,397
– – ﹤0.01% 2544
2025
Q4 		$127K Hold
9,397
– – ﹤0.01% 2491
2025
Q3 		$132K Hold
9,397
– – ﹤0.01% 2525
2025
Q2 		$110K Buy
+9,397
New +$131K ﹤0.01% 2491

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

MetLife Investment Management's BNTC Position: Q1 2026 in Review

MetLife Investment Management held its Benitec Biopharma (BNTC) position steady in Q1 2026 at 9,397 shares worth $100K. The position accounts for ﹤0.01% of the portfolio, ranked #2544.

MetLife Investment Management first reported a position in BNTC in Q2 2025 and has held it in 4 quarters since. The position peaked at $132K in Q3 2025. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

  • MetLife Investment Management held 9,397 shares of Benitec Biopharma worth $100K as of Q1 2026.
  • MetLife Investment Management left its Benitec Biopharma share count unchanged in Q1 2026.
  • Benitec Biopharma made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2544 holding.
  • MetLife Investment Management first reported a position in Benitec Biopharma in Q2 2025 and has held it in 4 quarters since.
  • MetLife Investment Management's Benitec Biopharma position peaked at $132K in Q3 2025.
  • 88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.